目的 探討重組人腦利鈉肽治療老年心力衰竭的臨床效果。方法 選取2018年1月—2019年12月安慶市立醫(yī)院收治的117例老年慢性心力衰竭患者作為研究對(duì)象，采用隨機(jī)數(shù)字表法將患者分為對(duì)照組（59例）和觀察組（58例）。兩組患者接受吸氧、臥床休息和常規(guī)抗心力衰竭治療。觀察組在對(duì)照組治療的基礎(chǔ)上給予注射用重組人腦利鈉肽，以1.5 μg/kg的負(fù)荷劑量靜脈推注，用1.5 mL 5%葡萄糖注射液稀釋，然后以0.007 5 μg/（kg·min）連續(xù)輸注72 h后，將速率控制為0.01 μg/（kg·min）。兩組療程均為2周。觀察兩組患者的臨床療效，同時(shí)比較兩組患者治療前后的心功能和血清學(xué)指標(biāo)水平。結(jié)果 治療后，觀察組的臨床療效分布優(yōu)于對(duì)照組（P<0.05）。治療后，兩組左室射血分?jǐn)?shù)（LVEF）、每搏輸出量（SV）值顯著升高，左室舒張末期內(nèi)徑（LVEDd）、左室收縮末期內(nèi)徑（LVESd）顯著降低（P<0.05）；且觀察組治療后的LVEF、SV值均高于對(duì)照組，LVEDd、LVESd值顯著低于對(duì)照組（P<0.05）。治療后，兩組患者的血清超敏C反應(yīng)蛋白（hs-CRP）、腦鈉肽（BNP）和同型半胱氨酸（Hcy）水平均顯著降低（P<0.05），且觀察組hs-CRP、BNP和Hcy水平均顯著低于對(duì)照組（P<0.05）。結(jié)論 重組人腦利鈉肽治療老年心力衰竭患者具有更好的臨床效果，可有效改善患者的心臟功能，降低hs-CRP、BNP的水平，值得在臨床上推廣使用。

Objective To investigate the clinical effect of recombinant human brain natriuretic peptide in treatment of elderly patients with heart failure. Methods A total of 117 elderly patients with chronic heart failure admitted to Anqing Municipal Hospital from January 2018 to December 2019 were selected as the study subjects, and the patients were divided into the control group (59 cases) and the observation group (58 cases) by random number table method. Patients in two groups received oxygen, rest, and routine antiheart failure therapy. Patients in the observation group were injected with Recombinant Human Brain Natriuretic Peptide for injection on the basis of control group, at a load dose of 1.5 μg/kg, diluted with 1.5 mL 5% glucose injection, and then continuously injected with 0.007 5 μg/(kg·min) for 72 h at a rate of 0.01 μg/(kg·min). The course of treatment in both groups was 2 weeks. The clinical efficacy in two groups was observed, and the cardiac function and serological index levels before and after treatment of the two groups were compared. Results After treatment, the distribution of clinical efficacy in the observation group was better than that in the control group (P<0.05). After treatment, LVEF and SV values in two groups were significantly increased, while LVEDd and LVESd were significantly decreased (P<0.05). In addition, the values of LVEF and SV after treatment in the observation group were higher than those in the control group, and the values of LVEDd and LVESd were significantly lower than those in the control group (P<0.05). After treatment, serum hs-CRP, BNP and Hcy levels in two groups were significantly decreased (P<0.05), and the levels of hs-CRP, BNP and Hcy in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Recombinant human brain natriuretic peptide has a better clinical effect in treatment of elderly patients with heart failure, can effectively improve the cardiac function of patients, reduce the level of hs-CRP and BNP, and is worth promoting in clinical use.

R972